Vanguard Group Inc. raised its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR – Free Report) by 16.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,561,880 shares of the biotechnology company’s stock after purchasing an additional 355,161 shares during the quarter. Vanguard Group Inc. owned 5.60% of Capricor Therapeutics worth $73,936,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CAPR. Parkside Financial Bank & Trust acquired a new position in Capricor Therapeutics during the third quarter worth $36,000. Russell Investments Group Ltd. lifted its stake in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 2,786 shares in the last quarter. GoalVest Advisory LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth $59,000. Tower Research Capital LLC TRC lifted its stake in Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares in the last quarter. Finally, PVG Asset Management Corp acquired a new position in Capricor Therapeutics during the third quarter worth $91,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.
Analyst Ratings Changes
CAPR has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research note on Wednesday. Roth Mkm restated a “buy” rating and set a $38.00 price target on shares of Capricor Therapeutics in a research note on Friday. Piper Sandler restated an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. B. Riley Financial upped their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $48.36.
Capricor Therapeutics Trading Down 1.7%
Capricor Therapeutics stock opened at $29.81 on Friday. The firm has a market capitalization of $1.72 billion, a P/E ratio of -12.85 and a beta of 0.48. The stock’s fifty day simple moving average is $31.79 and its 200-day simple moving average is $24.20. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37.
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Sell-side analysts predict that Capricor Therapeutics, Inc. will post 0.01 earnings per share for the current year.
Insider Buying and Selling at Capricor Therapeutics
In related news, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total value of $1,848,365.05. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total value of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. This trade represents a 75.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 172,529 shares of company stock worth $5,302,440 in the last three months. 9.20% of the stock is currently owned by corporate insiders.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Read More
- Five stocks we like better than Capricor Therapeutics
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
